检测驱虫斑鸠菊注射液导致矽肺患者血清蛋白的差异

发布时间：2018-03-20 05:26

本文选题：驱虫斑鸠菊注射　切入点：矽肺　出处：《新疆医科大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的:检测雾化吸入新疆维吾尔药驱虫斑鸠菊注射液(Vernonia Anthelmintica Willd Injection VAWI)导致矽肺患者血清蛋白的差异。方法:随机选取2014年11月至2017年3月新疆医科大学第五附属医院职防科矽肺壹期男性患者40例,按照1:1的比例将患者分为VAWI治疗组和基础治疗组,各20例,另选取同期健康体检者20例为正常组。基础治疗组给予包括氧疗、止咳、祛痰、平喘、抗炎等常规治疗,VAWI治疗组患者在基础治疗组的条件下加用驱虫斑鸠菊注射液,2毫升VAWI加入到10毫升0.9%生理盐水中进行雾化吸入,两组患者疗程均为10-15天。抽取两组患者治疗前后与正常组的血液进行离心,取血清,采用表面增强激光解吸离子化飞行质谱(SELDI-TOF-MS)技术检测三组之间血清蛋白的差异。结果:VAWI治疗组、基础治疗组、正常对照组之间平均年龄、体重指数、文化程度、吸烟指数差异均无统计学意义(p0.05)。正常组与基础治疗组前预测蛋白名称如下:complement c3 frag、amyloid beta a4 protein、hepcidin、fibrinogen alpha chain frag、neurosecretory protein vgf frag、alpha-1-antichymotrypsin frag、apolipoprotein c-i、transthyretin、apolipoprotein c-iii、apolipoprotein a-ii、cystatin-c。正常组与基础治疗组后预测蛋白名称如下:amyloid beta a4 protein、hepcidin、fibrinogen alpha chain frag、neurosecretory、alpha-1-antichymotrypsin frag、apolipoprotein c-i、transthyretin、osteopontin frag、apolipoprotein c-iii、apolipoprotein a-ii、cystatin-c。基础治疗组前与基础治疗组后预测蛋白名称如下:amyloid beta a4 protein、plasma protease c1inhibitor frag、alpha-1-antichymotrypsin frag、neurosecretory protein vgf frag、fibrinogen alpha chain frag、osteopontin frag。VAWI治疗组前与VAWI治疗组后预测蛋白名称如下:amyloid beta a4 protein、fibrinogen alpha chain frag、neutrophil defensin 1,neutrophil defensin 3、neurosecretory protein vgf frag、plasma protease c1 inhibitor frag、alpha-1-antichymotrypsin frag、apolipoprotein c-i、transthyretin、osteopontin frag、hemoglobin subunit beta、apolipoprotein a-ii、cystatin-c。血清蛋白的表达差异均有统计学意义(p0.05,阈值1)。结论:矽肺患者基础治疗前、后均与正常健康人群存在血清差异蛋白的表达,矽肺患者进行基础治疗可引起血清差异蛋白的表达,驱虫斑鸠菊注射液可导致矽肺患者血清差异蛋白的表达。
[Abstract]:Objective: to detect the difference of serum protein in silicosis patients induced by aerosol inhalation of Vernonia Anthelmintica Willd Injection VAWI. Methods: from November 2014 to March 2017, 5th affiliated Hospital of Xinjiang Medical University was randomly selected. A total of 40 male patients with silicosis in the Department of Vocational Protection, According to the ratio of 1: 1, the patients were divided into two groups: VAWI group (n = 20) and basic treatment group (n = 20). In the basic treatment group, 2 ml VAWI was added to 10 ml of normal saline in 10 ml of normal saline for atomization inhalation, and 2 ml of VAWI was added to 10 ml of normal saline. The course of treatment in both groups was 10-15 days. The blood samples from the two groups before and after treatment were centrifuged and serum samples were taken. Surface enhanced laser desorption ionization mass spectrometry (SELDI-TOF-MS) was used to detect the difference of serum protein among the three groups. There was no significant difference in smoking index between normal group and basic treatment group. The prepredicted protein names of normal group and basic treatment group were as follows: complement c3 fragamyloid beta a4 protein hepcidal fibrinogen alpha chain fragment secretory protein vgf fragment alpha-1-antichymotrypsin fragapolipoprotein c-itransretinopolipoprotein iiiapolipoprotein a-iapolipoprotein a-iapolipoprotein a-iapolipoprotein a iiapolipoprotein a iiapolipoprotein a iiapolipoprotein a iiapolipoprotein a iiapolipoprotein a iiapolipoprotein a cystatin-c.After the normal group and the basic treatment group, the prediction protein name was as follows: amyloid beta a4 hepcidin fibrinogen. Alpha chain fragmental neurosecretory alpha-1-antichymotrypsin apolipoprotein c-i transthyretinopontin / apolipoprotein c-iiiiiapolipoprotein a-iiapolipoprotein a-iiapolipoprotein a-iiolipoprotein cystatin-c. The names of the predictive proteins before and after treatment are as follows: amyloid beta a4 protein / protease C1fraginhibitor protease C1frag-secretory protein vgf fragmental protein vgf fragmental protein vgf fragmentogen alpha chain osteopontin frag.VAWI and VAWI treatment groups. The names of the predictive proteins before and after VAWI treatment are as follows: amyloid beta a4 protein alpha chain alpha defensin defensin defensin. 1neutrophil defensin 3 neurosecretory protein vgf fragment plasma protease C1 inhibitor fragment alpha-1-antichymotrypsin fragment apolipoprotein c-iopontin fragment protein subunit betaapolipoprotein a-iiapolipoprotein a-iidia cystatin-c.The difference of serum protein expression was significant (p0.05). Conclusion: before basic therapy for silicosis patients, there are significant differences in the expression of serum protein (p 0.05). After the treatment of silicosis patients, the expression of serum differential proteins could be induced by basic therapy, and the expression of serum differential proteins of silicosis patients could be induced by the injection of repellent turtledove chrysanthemum.
【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R135.2

【参考文献】